Marinus Pharmaceuticals, Inc. (MRNS) Financials

MRNS Assets vs Liabilities
DateAssetsLiabilities
Sept. 30, 2024 63.6 million 130.4 million
June 30, 2024 87.1 million 134.4 million
March 31, 2024 137.4 million 153.8 million
Dec. 31, 2023 170.9 million 154.1 million

MRNS Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
Sept. 30, 2024 -20.6 million 4.8 million
June 30, 2024 -30.9 million 4.9 million
March 31, 2024 -37.5 million 5.2 million
Dec. 31, 2023 -27.0 million 3.9 million

MRNS Net Income

No data available :(

MRNS Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
Sept. 30, 2024 42.2 million 41.7 million -
June 30, 2024 64.7 million 80.7 million 989000
March 31, 2024 113.3 million 93.3 million 1.9 million
Dec. 31, 2023 150.3 million 95.8 million 1.4 million

MRNS Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
Sept. 30, 2024 57.2 million
June 30, 2024 57.1 million
March 31, 2024 56.9 million
Dec. 31, 2023 56.7 million

MRNS Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
Sept. 30, 2024 1.1 million 16.3 million 12.6 million -
June 30, 2024 38000 20.9 million 16.7 million 3.1 million
March 31, 2024 - 24.0 million 18.6 million -
Dec. 31, 2023 34000 26.3 million 15.4 million -364000

MRNS Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
Sept. 30, 2024 8.5 million 714000
June 30, 2024 8.1 million 875000
March 31, 2024 7.7 million 887000
Dec. 31, 2023 7.2 million 1.0 million

MRNS Revenue by Segment
Graph available only for paid members. Upgrade to see it.

MRNS

Price: $0.55

52 week price:
0.22
10.50

Earnings Per Share: -2.47 USD

Exchange: NGM

Sector: Healthcare

Industry: Biotechnology

Country: United States

Volume: 214200

Ebitda: -19.9 million

Market Capitalization: 30.4 million

Links: